BRG publications

BRG Publications:

Acta Polonie Pharmaceutica

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2821%2900331-8/fulltext

https://jpro.springeropen.com/articles/10.1186/s41687-024-00805-w

https://link.springer.com/article/10.1007/s00415-024-12236-0

https://www.sciencedirect.com/science/article/pii/S0960896623006703

https://www.gimjournal.org/article/S1098-3600%2822%2900210-6/fulltext

https://link.springer.com/article/10.1007/s00415-024-12843-x

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200208

https://imux.com/immunic-announces-publication-of-extended-data-from-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis-in-the-peer-reviewed-journal/

https://www.neurologylive.com/view/long-term-extension-data-demonstrates-sustained-effect-vidofludimus-calcium-relapsing-remitting-multiple-sclerosis

https://www.rarediseaseadvisor.com/news/vidofludimus-calcium-effective-in-patients-with-relapsing-remitting-ms/

P.J. Rudzki, K. Jarus-Dziedzic, D. Włodarczyk, M. Kaza, P. Pankiewicz, A. Gierczak-Pachulska, M. Banach, B. Zygmunt, C. Piwowarczyk, P. Żero, D. Rabczenko, A. Segiet-Święcicka, M. Wieczorek: First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects. Front Pharmacol. 16 (2025) 1583723. doi: 10.3389/fphar.2025.1583723 IF2024 = 4.800; MEiN2024 = 100

K. Bazydło-Guzenda, K. Jarus-Dziedzic, A. Gierczak-Pachulska, P. Buda, P.J. Rudzki, K. Buś-Kwaśnik, E. Juszczyk, E. Tratkiewicz, D. Rabczenko, A. Segiet-Święcicka, M. Wieczorek: First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration. Diabetes Obes. Metab. 26 (2024):1376-1385. IF2022 = 5.800; MEiN2023 = 140

M. Kaza, A. Gierczak-Pachulska, K. Jarus-Dziedzic, O. Czerepow-Bielik, A. Segiet-Święcicka, G. Huszcza, M. Hulak, D. Rabczenko, P.J. Rudzki : Relative bioavailability of ticagrelor from hard capsules and film-coated tablets in healthy Caucasian volunteers. Acta Pol. Pharm. Drug Res. 82 (1) (2025) 37-48, doi: 10.32383/appdr/205967. IF2023=0,4; MNiSW2024 = 100

A. Gierczak-Pachulska, M. Kaza, K. Jarus-Dziedzic, O. Czerepow-Bielik, A. Segiet-Święcicka, G. Huszcza, K. Sidoruk, D. Rabczenko, P.J. Rudzki : Bioequivalence of rivaroxaban hard capsules vs. film-coated tablets in healthy caucasian volunteers. Acta Pol. Pharm. Drug Res. 81 (1) (2024) 97-108. IF2023=0,4; MNiSW2024 = 100

P.J. Rudzki, K. Jarus-Dziedzic, M. Filist, E. Gilant, K. Buś-Kwaśnik, A. Leś, M. Sasinowska-Motyl, Ł. Nagraba, M. Bujalska-Zadrożny : Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. Pharmacol Rep. 73 (2021) 604-614. IF2020=3,024; MNiSW2021 = 100

K. Bazydlo-Guzenda, A. Gierczak-Pachulska, K. Jarus-Dziedzic, P. Rudzki, M. Wieczorek: 761-P: Safety and Pharmacokinetic Study of GPR40 Agonist (CPL207280) after a Single Dose in Healthy Subjects, Diabetes 70(Supplement 1) (2021) 116-117 IF2020 = 10,122

O. Czerepow-Bielik, M. Kaza, K. Jarus-Dziedzic, D. Włodarczyk, A. Gierczak-Pachulska, P. Żero, A. Segiet-Święcicka, D. Rabczenko, P.J. Rudzki, M. Wieczorek: Effect of food on pharmacokinetics of drug candidate CPL409116 and its M3 metabolite in healthy volunteers, Accord 2024 Interdisciplinary Conference on Drug Sciences, Warszawa, 23-25 V 2024

M. Kaza, B. Mantur, K. Abramski, D. Włodarczyk, K. Jarus-Dziedzic, P.J. Rudzki, M. Wieczorek: LC-MS/MS determination of a drug candidate CPL409116 and its M3 metabolite in human plasma, 4th ORBIS School on Biopharmaceutical Evaluation of Dosage Forms and Drug Delivery, Prague (Czechia), 07-08 IX 2022

P.J. Rudzki, S. Janowska, P. Gałecki, K. Jarus-Dziedzic, D. Rabczenko, A. Segiet, M. Wieczorek: Pharmacokinetics of esketamine inhaled as dry powder in healthy subjects and patients, Accord 2022 Interdisciplinary Conference on Drug Sciences, Warszawa, 26-28 V 2022

E. Juszczyk, K. Kisło, E. Tratkiewicz, K. Bazydło-Guzenda, A. Gierczak-Pachulska, P.J. Rudzki, J. Paszkowska, D. Danielak, J. Sczodrok, G. Garbacz, K. Jarus-Dziedzic, K. Buś-Kwaśnik, M. Wieczorek: Effect of food on human pharmacokinetics of CPL207280 –

a new GPR40 agonist: in vitro and in vivo studies, Accord 2022 Interdisciplinary Conference on Drug Sciences, Warszawa, 26-28 V 2022

M. Kaza, D. Włodarczyk, K. Abramski, K. Jarus-Dziedzic, B. Mantur, D. Rabczenko, P.J. Rudzki, A. Segiet, M. Wieczorek: First-in-human pharmacokinetic study of a JAK/ROCK dual inhibitor CPL409116, Accord 2022 Interdisciplinary Conference on Drug Sciences, Warszawa, 26-28 V 2022

K. Bazydlo-Guzenda, K. Jarus-Dziedzic, A. Gierczak-Pachulska, K. Buś-Kwaśnik, P.J. Rudzki, M.Wieczorek: Safety and pharmacokinetic study of CPL207280, a novel GPR40 receptor agonist, after a multiple dose in healthy volunteers, 57th Annual Meeting of European Association for the Study of Diabetes (on-line), 27 IX - 01 X 2021

K. Bazydlo-Guzenda, A. Gierczak-Pachulska, K. Jarus-Dziedzic, P. Rudzki, M. Wieczorek: 761-P: Safety and Pharmacokinetic Study of GPR40 Agonist (CPL207280) after a Single Dose in Healthy Subjects, 81st Scientific Sessions, American Diabetes Association (ADA2021, on-line), 25-29 VI 2021

M. Kaza, O. Czerepow-Bielik, A. Segiet-Święcicka, A. Gierczak-Pachulska, K. Jarus-Dziedzic, G. Huszcza, K. Sidoruk, D. Rabczenko, P.J. Rudzki: Porównanie dostępności biologicznej rywaroksabanu po podaniu kapsułek i tabletek powlekanych zdrowym ochotnikom. VI Śląskie Farmaceutyczne Spotkanie Naukowe „Od Nauki do Pacjenta”, Katowice (on-line), 21 XI 2023

P. J. Rudzki, K. Jarus-Dziedzic, M. Filist, E. Gilant, K. Buś-Kwaśnik, A. Leś, M. Sasinowska-Motyl, Ł. Nagraba, M. Bujalska-Zadrożny: Influence of magnesium ions on tramadol pharmacokinetics in humans. XI Multidyscyplinarna Konferencja Nauki o Leku, Warszawa, 14-16 XI 2018

All BRG Studies are listed in the ABOUT US content: section CLINICAL STUDIES

ll[

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2026 © Bio Research Group. All rights reserved.

 

scroll to top ▲